Skip to main content
Erschienen in: Metabolic Brain Disease 5/2017

29.06.2017 | Short Communication

SSADH deficiency in an Italian family: a novel ALDH5A1 gene mutation affecting the succinic semialdehyde substrate binding site

verfasst von: Sara Leo, Concetta Capo, Bianca Maria Ciminelli, Federico Iacovelli, Giovanna Menduti, Silvia Funghini, Maria Alice Donati, Mattia Falconi, Luisa Rossi, Patrizia Malaspina

Erschienen in: Metabolic Brain Disease | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

SSADH deficiency (SSADHD) is a rare autosomal recessively inherited metabolic disorder. It is associated with mutations of ALDH5A1 gene, coding for the homotetrameric enzyme SSADH. This enzyme is involved in γ-aminobutyric acid (GABA) catabolism, since it oxidizes succinic semialdehyde (SSA) to succinate. Mutations in ALDH5A1 gene result in the abnormal accumulation of γ-hydroxybutyrate (GHB), which is pathognomonic of SSADHD. In the present report, diagnosis of SSADHD in a three-month-old female was achieved by detection of high levels of GHB in urine. Sequence analysis of ALDH5A1 gene showed that the patient was a compound heterozygote for c.1226G > A (p.G409D) and the novel missense mutation, c.1498G > C (p.V500 L). By ALDH5A1 gene expression in transiently transfected HEK293 cells and enzyme activity assays, we demonstrate that the p.V500 L mutation, despite being conservative, produces complete loss of enzyme activity. In silico protein modelling analysis and evaluation of tetramer destabilizing energies suggest that structural impairment and partial occlusion of the access channel to the active site affect enzyme activity. These findings add further knowledge on the missense mutations associated with SSADHD and the molecular mechanisms underlying the loss of the enzyme activity.
Literatur
Zurück zum Zitat Akaboshi S, Hogema BM, Novelletto A, Malaspina P, Salomons GS, Maropoulos GD, Jakobs C, Grompe M, Gibson KM (2003) Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat 22:442–450CrossRefPubMed Akaboshi S, Hogema BM, Novelletto A, Malaspina P, Salomons GS, Maropoulos GD, Jakobs C, Grompe M, Gibson KM (2003) Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat 22:442–450CrossRefPubMed
Zurück zum Zitat Blasi P, Pilo-Boyl P, Ledda M, Novelletto A, Gibson KM, Jakobs C, Hogema B, Akaboshi S, Loreni F, Malaspina P (2002) Structure of human succinic semialdehyde dehydrogenase gene: identification of promoter region and alternatively processed isoforms. Mol Genet Metab 76:348–362CrossRefPubMed Blasi P, Pilo-Boyl P, Ledda M, Novelletto A, Gibson KM, Jakobs C, Hogema B, Akaboshi S, Loreni F, Malaspina P (2002) Structure of human succinic semialdehyde dehydrogenase gene: identification of promoter region and alternatively processed isoforms. Mol Genet Metab 76:348–362CrossRefPubMed
Zurück zum Zitat Di Rosa G, Malaspina P, Blasi P, Dionisi-Vici C, Rizzo C, Tortorella G, Crutchfield SR, Gibson KM (2009) Visual evoked potentials in succinate semialdehyde dehydrogenase (SSADH) deficiency. J Inherit Metab Dis 32(Suppl 1):S201–S205CrossRefPubMed Di Rosa G, Malaspina P, Blasi P, Dionisi-Vici C, Rizzo C, Tortorella G, Crutchfield SR, Gibson KM (2009) Visual evoked potentials in succinate semialdehyde dehydrogenase (SSADH) deficiency. J Inherit Metab Dis 32(Suppl 1):S201–S205CrossRefPubMed
Zurück zum Zitat Gibson KM, Hoffmann GF, Hodson AK, Bottiglieri T, Jakobs C (1998) 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics 29:14–22CrossRefPubMed Gibson KM, Hoffmann GF, Hodson AK, Bottiglieri T, Jakobs C (1998) 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics 29:14–22CrossRefPubMed
Zurück zum Zitat Kim YG, Lee S, Kwon OS, Park SY, Lee SJ, Park BJ, Kim KJ (2009) Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J 28:959–968CrossRefPubMedPubMedCentral Kim YG, Lee S, Kwon OS, Park SY, Lee SJ, Park BJ, Kim KJ (2009) Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J 28:959–968CrossRefPubMedPubMedCentral
Zurück zum Zitat Lemes A, Blasi P, Gonzales G, Russi ME, Quadrelli R, Novelletto A, Malaspina P (2006) Succinic semialdehyde dehydrogenase (SSADH) deficiency: molecular analysis in a south American family. J Inherit Metab Dis 29:587CrossRefPubMed Lemes A, Blasi P, Gonzales G, Russi ME, Quadrelli R, Novelletto A, Malaspina P (2006) Succinic semialdehyde dehydrogenase (SSADH) deficiency: molecular analysis in a south American family. J Inherit Metab Dis 29:587CrossRefPubMed
Zurück zum Zitat Leuzzi V, Di Sabato ML, Deodato F, Rizzo C, Boenzi S, Carducci C, Malaspina P, Liberanome C, Dionisi-Vici C (2007) Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency. Neurology 68:1320–1321CrossRefPubMed Leuzzi V, Di Sabato ML, Deodato F, Rizzo C, Boenzi S, Carducci C, Malaspina P, Liberanome C, Dionisi-Vici C (2007) Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency. Neurology 68:1320–1321CrossRefPubMed
Zurück zum Zitat Malaspina P, Roullet JB, Pearl PL, Ainslie GR, Vogel KR, Gibson KM (2016) Succinic semialdehyde dehydrogenase deficiency (SSADHD): pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism. Neurochem Int 99:72–84CrossRefPubMed Malaspina P, Roullet JB, Pearl PL, Ainslie GR, Vogel KR, Gibson KM (2016) Succinic semialdehyde dehydrogenase deficiency (SSADHD): pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism. Neurochem Int 99:72–84CrossRefPubMed
Zurück zum Zitat Mendes J, Guerois R, Serrano L (2002) Energy estimation in protein design. Curr Opin Struct Biol 12:441–446CrossRefPubMed Mendes J, Guerois R, Serrano L (2002) Energy estimation in protein design. Curr Opin Struct Biol 12:441–446CrossRefPubMed
Zurück zum Zitat Parviz M, Vogel K, Gibson KM, Pearl PL (2014) Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies. J Pediatr Epilepsy 3:217–227CrossRefPubMedPubMedCentral Parviz M, Vogel K, Gibson KM, Pearl PL (2014) Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies. J Pediatr Epilepsy 3:217–227CrossRefPubMedPubMedCentral
Zurück zum Zitat Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM (2003) Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 54(Suppl 6):S73–S80CrossRefPubMed Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM (2003) Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 54(Suppl 6):S73–S80CrossRefPubMed
Zurück zum Zitat Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L (2005) The FoldX web server: an online force field. Nucleic Acids Res 33:W382–W388CrossRefPubMedPubMedCentral Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L (2005) The FoldX web server: an online force field. Nucleic Acids Res 33:W382–W388CrossRefPubMedPubMedCentral
Zurück zum Zitat Studer RA, Christin PA, Williams MA, Orengo CA (2014) Stability-activity tradeoffs constrain the adaptive evolution of RubisCO. Proc Natl Acad Sci U S A 111:2223–2228CrossRefPubMedPubMedCentral Studer RA, Christin PA, Williams MA, Orengo CA (2014) Stability-activity tradeoffs constrain the adaptive evolution of RubisCO. Proc Natl Acad Sci U S A 111:2223–2228CrossRefPubMedPubMedCentral
Zurück zum Zitat Tanaka K, West-Dull A, Hine DG, Lynn TB, Lowe T (1980) Gas-chromatographic method of analysis for urinary organic acids. II. Description of the procedure, and its application to diagnosis of patients with organic acidurias. Clin Chem 26:1847–1853PubMed Tanaka K, West-Dull A, Hine DG, Lynn TB, Lowe T (1980) Gas-chromatographic method of analysis for urinary organic acids. II. Description of the procedure, and its application to diagnosis of patients with organic acidurias. Clin Chem 26:1847–1853PubMed
Metadaten
Titel
SSADH deficiency in an Italian family: a novel ALDH5A1 gene mutation affecting the succinic semialdehyde substrate binding site
verfasst von
Sara Leo
Concetta Capo
Bianca Maria Ciminelli
Federico Iacovelli
Giovanna Menduti
Silvia Funghini
Maria Alice Donati
Mattia Falconi
Luisa Rossi
Patrizia Malaspina
Publikationsdatum
29.06.2017
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 5/2017
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-017-0058-5

Weitere Artikel der Ausgabe 5/2017

Metabolic Brain Disease 5/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.